GRAIL (GRAL) to Release Quarterly Earnings on Wednesday

Posted by Brian Himes on Aug 3rd, 2026

GRAIL (NASDAQ:GRAL – Get Free Report) is expected to release its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect GRAIL to announce earnings of ($2.66) per share and revenue of $42.39 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

GRAIL (NASDAQ:GRAL – Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($2.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.76) by $0.47. GRAIL had a negative return on equity of 16.42% and a negative net margin of 253.22%.The business had revenue of $40.78 million for the quarter, compared to analyst estimates of $39.16 million. On average, analysts expect GRAIL to post $-11 EPS for the current fiscal year and $-11 EPS for the next fiscal year.

GRAIL Stock Performance

NASDAQ:GRAL traded up $2.44 during trading hours on Monday, hitting $71.00. The stock had a trading volume of 50,933 shares, compared to its average volume of 932,531. GRAIL has a one year low of $29.95 and a one year high of $118.84. The business’s 50 day moving average is $66.78 and its 200-day moving average is $67.33. The company has a market cap of $3.05 billion, a price-to-earnings ratio of -6.81 and a beta of 3.22.

Insider Buying and Selling

In other GRAIL news, insider Andrew John Partridge sold 1,491 shares of the company’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $61.08, for a total value of $91,070.28. Following the transaction, the insider directly owned 163,738 shares in the company, valued at $10,001,117.04. The trade was a 0.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 1.83% of the stock is currently owned by company insiders.

Institutional Trading of GRAIL

Institutional investors have recently added to or reduced their stakes in the company. Comerica Bank raised its holdings in GRAIL by 59.2% in the 3rd quarter. Comerica Bank now owns 465 shares of the company’s stock valued at $27,000 after acquiring an additional 173 shares in the last quarter. Intesa Sanpaolo S.p.A. acquired a new position in shares of GRAIL during the 4th quarter worth $44,000. NewEdge Advisors LLC lifted its holdings in shares of GRAIL by 390.3% in the first quarter. NewEdge Advisors LLC now owns 1,760 shares of the company’s stock worth $45,000 after acquiring an additional 1,401 shares during the last quarter. Ankerstar Wealth LLC acquired a new stake in GRAIL in the fourth quarter valued at approximately $45,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of GRAIL by 28.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,835 shares of the company’s stock valued at $76,000 after acquiring an additional 623 shares in the last quarter.

Wall Street Analyst Weigh In

Several research analysts recently commented on GRAL shares. The Goldman Sachs Group assumed coverage on shares of GRAIL in a report on Friday, June 5th. They set a “neutral” rating and a $60.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a research note on Friday, July 17th. Wall Street Zen raised GRAIL from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Piper Sandler boosted their target price on shares of GRAIL from $54.00 to $56.00 and gave the stock a “neutral” rating in a report on Wednesday, May 6th. Finally, TD Cowen restated a “buy” rating on shares of GRAIL in a research note on Wednesday, July 15th. Four investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $67.78.

Check Out Our Latest Research Report on GRAIL

GRAIL Company Profile

(Get Free Report)

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.